lopinavir/ritonavir

lopinavir/ritonavir
Drug name	Lopinavir/ritonavir
Tradename	Kaletra
Class	Antiretroviral combination
Routes of administration	Oral
Metabolism	Hepatic (CYP3A4)
Elimination half life	Lopinavir ~5–6 h; Ritonavir ~3–5 h (boosting effect prolongs)

lopinavir/ritonavir is a fixed-dose combination antiretroviral medication used primarily in the treatment of human immunodeficiency virus infection, combining the protease inhibitor lopinavir with the pharmacoenhancer ritonavir. The combination pairs a therapeutic agent with a metabolic inhibitor to increase plasma concentrations, and it has been evaluated in clinical trials, public health programs, and emergency responses involving viral infections. Major global health agencies and pharmaceutical entities have documented its role in antiretroviral therapy guidelines and procurement.

Medical uses

Lopinavir/ritonavir is indicated for treatment of Human Immunodeficiency Virus infection in adults and pediatric populations where protease inhibitor–based regimens are appropriate, and has been included in treatment protocols endorsed by agencies such as the World Health Organization, United States Department of Health and Human Services, and national programs like the National Health Service (England). Clinical trials comparing lopinavir/ritonavir–based regimens with other antiretroviral combinations have been conducted at institutions including National Institutes of Health, University of Oxford, and University of California, San Francisco, and reported in journals associated with The Lancet and New England Journal of Medicine. The drug has also been studied off-label during outbreaks of emerging viruses where protease inhibitors were hypothesized to have activity, with evaluations by organizations such as Centers for Disease Control and Prevention and the European Medicines Agency.

Contraindications and precautions

Contraindications include known hypersensitivity to lopinavir, ritonavir, or any formulation components, and concurrent administration with medicinal products highly dependent on Cytochrome P450 3A4 metabolism where elevated concentrations may cause life-threatening events, as advised by regulatory bodies like the Food and Drug Administration and European Medicines Agency. Caution is advised in patients with pre-existing hepatic impairment monitored by tertiary centers such as Mayo Clinic and specialist hepatology units affiliated with Johns Hopkins Hospital; clinicians in settings such as Massachusetts General Hospital often assess liver enzymes and lipid profiles before initiation. Pregnancy registries maintained by organizations including Antiretroviral Pregnancy Registry and cohorts from Imperial College London have informed use during gestation, requiring risk–benefit discussion in multidisciplinary teams that include experts from World Health Organization programs.

Adverse effects

Common adverse effects reported in randomized controlled trials performed at institutions like Harvard Medical School and University of California, San Francisco include gastrointestinal disturbances (nausea, diarrhea), metabolic changes (hypertriglyceridemia, hypercholesterolemia), and hepatotoxicity monitored by centers such as Cleveland Clinic. Long-term use has been associated with lipodystrophy syndromes described in cohort studies from University College London and alterations in glucose metabolism observed in research from University of Toronto. Case reports and pharmacovigilance summaries compiled by the European Medicines Agency and Food and Drug Administration document rare events such as pancreatitis and severe skin reactions that require specialist consultation with dermatology and gastroenterology services at tertiary hospitals like Guy's and St Thomas' NHS Foundation Trust.

Interactions

Ritonavir is a potent inhibitor of Cytochrome P450 3A4 and affects the pharmacokinetics of numerous agents, resulting in clinically significant interactions with drugs including certain antiarrhythmics used in Mayo Clinic protocols, sedative-hypnotics discussed in American Psychiatric Association guidance, and some immunosuppressants managed by transplant centers such as Cleveland Clinic Transplant Center. Co-administration with agents such as rifampicin, certain statins named in guidelines from American College of Cardiology, and some direct-acting antivirals has produced recommendations from regulatory agencies like the Food and Drug Administration to avoid or adjust dosing. Drug interaction resources maintained by Liverpool HIV Pharmacology Group and formularies at institutions such as Johns Hopkins Hospital are commonly consulted for individualized management.

Pharmacology

Lopinavir acts as an inhibitor of the HIV-1 protease enzyme, preventing proteolytic cleavage of gag-pol polyproteins and thereby impairing virion maturation, a mechanism characterized in basic science laboratories at institutions including Rockefeller University and Cold Spring Harbor Laboratory. Ritonavir, initially developed as a protease inhibitor, exerts a pharmacokinetic boosting effect through potent inhibition of Cytochrome P450 3A4 in hepatocytes studied at National Institutes of Health, raising lopinavir plasma concentrations and prolonging its half-life; this principle is analogous to pharmacologic boosting strategies discussed in pharmacology texts from Oxford University Press. Pharmacokinetic profiles, protein binding characteristics, and hepatic metabolism pathways have been described in clinical pharmacology reports by groups at University of California, San Diego and University of Liverpool.

History and development

The combination was developed and commercialized by multinational pharmaceutical companies in collaboration with academic research centers; pivotal development work involved partnerships with institutions such as AbbVie (formerly part of Pharmaceutical Research and Manufacturers of America collaborations), and clinical development programs included trial sites at University of Cape Town and Stellenbosch University. Early regulatory submissions and landmark trials were reviewed by agencies including the Food and Drug Administration and European Medicines Agency, and implementation in global treatment programs was influenced by policy discussions at World Health Assembly meetings and procurement mechanisms coordinated by UNICEF and The Global Fund.

Regulatory status and availability

Lopinavir/ritonavir has been approved for use in many jurisdictions following decisions by regulators such as the Food and Drug Administration and European Medicines Agency, and its availability in low- and middle-income countries has been facilitated through procurement by organizations including The Global Fund, United Nations Children's Fund, and Clinton Health Access Initiative. Patent, generic manufacturing, and access initiatives involving entities like World Health Organization prequalification and manufacturers in India have affected cost and distribution, with listings on national essential medicines lists in countries advised by agencies such as Pan American Health Organization and national ministries of health.

Category:Antiretroviral drugs